Skip to main content

Advertisement

SpringerLink
Log in

Establishing a Link between Oncogenes and Tumor Angiogenesis

  • Minireview
  • Published:
Molecular Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Hanahan D, Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364.

    Article  CAS  PubMed  Google Scholar 

  2. Fearon ER, Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759–767.

    Article  CAS  PubMed  Google Scholar 

  3. Folkman J. (1971) Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285: 1182–1186.

    Article  CAS  PubMed  Google Scholar 

  4. Folkman J. (1972) Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 175: 409–416.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Folkman J. (1990) What is the evidence that tumors are angiogenesis-dependent? J. Natl. Cancer Inst. 82: 4–6.

    Article  CAS  PubMed  Google Scholar 

  6. Bouck N, Stellmach V, Hsu SC. (1996) How tumors become angiogenic. Adv. Cancer Res. 69: 135–174.

    Article  CAS  PubMed  Google Scholar 

  7. Kerbel RS. (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13: 31–36.

    Article  CAS  PubMed  Google Scholar 

  8. Boehm T, Folkman J, Browder T, et al. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404–407.

    Article  CAS  PubMed  Google Scholar 

  9. Kerbel RS. (1997) A cancer therapy resistant to resistance. Nature 390: 335–336.

    Article  CAS  PubMed  Google Scholar 

  10. Folkman J, D’Amore PA. (1996) Blood vessel formation: What is its molecular basis? Cell 87: 1153–1155.

    Article  CAS  PubMed  Google Scholar 

  11. Terman BI, Dougher-Vermazen M. (1996) Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev. 15: 159–163.

    Article  CAS  PubMed  Google Scholar 

  12. Thomas KA. (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271: 603–606.

    Article  CAS  PubMed  Google Scholar 

  13. Stromblad S, Cheresh DA. (1998) Cell adhesion and angiogenesis. Trends Cell Biol. 6: 462–468.

    Article  Google Scholar 

  14. Brooks PC. (1996) Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev. 15: 187–194.

    Article  CAS  PubMed  Google Scholar 

  15. Bischoff J. (1995) Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol 5: 69–74.

    Article  CAS  PubMed  Google Scholar 

  16. Folkman J. (1995) Angiogenesis inhibitors generated by tumors. Mol Med. 1: 120–122.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Baird A, Klagsbrun M. (1991) The fibroblast growth factor family. Cancer Cells 3: 239–243.

    PubMed  CAS  Google Scholar 

  18. Rak J, Kerbel RS. (1997) bFGF and tumor angiogenesis—back in the limelight? Nat. Med. 3: 1083–1084.

    Article  CAS  PubMed  Google Scholar 

  19. Dameron KM, Volpert OV, Tainsky MA, et al. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582–1584.

    Article  CAS  PubMed  Google Scholar 

  20. Bouck N. (1990) Tumor angiogenesis: The role of oncogenes and tumor suppressor genes. Cancer Cells 2: 179–185.

    PubMed  CAS  Google Scholar 

  21. Cleveland DW, Lopata MA, MacDonald RJ, et al. (1980) Number and evolutionary conservation of alpha- and beta-tubulin and cytoplasmic beta-and gamma-actin genes using specific cloned cDNA probes. Cell 20: 95–105.

    Article  CAS  PubMed  Google Scholar 

  22. Roberts AB, Sporn MB, Assoian RK, et al. (1986) Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. U.S.A. 83: 4167–4171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Iberg N, Rogelj S, Fanning P, et al. (1989) Purification of 18- and 22-kDa forms of basic fibroblast growth factor from rat cells transformed by the ras oncogene. J. Biol Chem. 264: 19951–19955.

    PubMed  CAS  Google Scholar 

  24. Tannock I. (1978) Cell kinetics and chemotherapy: A critical review. Cancer Treat. Reports 62: 1117–1133.

    CAS  Google Scholar 

  25. Olive PL, Durand RE. (1994) Drug and radiation resistance in spheroids: Cell contact and kinetics. Cancer Metastasis Rev. 13: 121–138.

    Article  CAS  PubMed  Google Scholar 

  26. Berges RR, Vukanovic J, Epstein J, et al. (1995) Implication of cell kinetic changes during the progression of human prostatic carcinoma. Clin. Cancer Res. 1: 473–480.

    PubMed  PubMed Central  CAS  Google Scholar 

  27. St.Croix B, Florenes VA, Rak JW, et al. (1996) Impact of the cyclin dependent kinase inhibitor p27Kip 1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat. Med. 2: 1204–1210.

    Article  CAS  PubMed  Google Scholar 

  28. Kohl NE, Mosser SD, deSolms SJ, et al. (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934–1942.

    Article  CAS  PubMed  Google Scholar 

  29. James GL, Golstein JL, Brown MS, et al. (1993) Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 260: 1937–1942.

    Article  CAS  PubMed  Google Scholar 

  30. Mendelsohn J, Fan Z. (1997) Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. 89: 341–343.

    Article  CAS  PubMed  Google Scholar 

  31. Fendly BM, Winget M, Hudziak RM, et al. (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50: 1550–1558.

    PubMed  CAS  Google Scholar 

  32. Goldstein NI, Prewett M, Zuklys K, et al. (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1: 1311–1318.

    PubMed  CAS  Google Scholar 

  33. Kohl NE, Omer CA, Conner MW, et al. (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1: 792–797.

    Article  CAS  PubMed  Google Scholar 

  34. Ohnishi Y, Nakamura H, Yoshimura M, et al. (1995) Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody. Br. J. Cancer 71: 969–973.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Rak J, Mitsuhashi Y, Erdos V, et al. (1995) Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: Suppression by expression of a mutant c-H-ras oncogene. J. Cell Biol 131: 1587–1598.

    Article  CAS  PubMed  Google Scholar 

  36. Lebowitz P, Sakamuro D, Prendergast GC. (1997) Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. 57: 708–713.

    PubMed  CAS  Google Scholar 

  37. Barrington RE, Subler MA, Rands E, et al. (1998) A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18: 85–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Rak J, Mitsuhashi Y, Bayko L, et al. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55: 4575–4580.

    PubMed  CAS  Google Scholar 

  39. Folkman J. (1995) Clinical applications of research on angiogenesis. New Engl J. Med. 333: 1757–1763.

    Article  CAS  PubMed  Google Scholar 

  40. O’Reilly MS, Holmgren L, Chen C, et al. (1996) Angiostatin induces canal sustains dormancy of human tumors in mice. Nat. Med. 2: 689–692.

    Article  PubMed  Google Scholar 

  41. Cheng SY, Huang HJ, Nagane M, et al. (1996) Suppression of glioblastoma angiogenicity and tu-morigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U.S.A. 93: 8502–8507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Benjamin LE, Keshet E. (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangio-blastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. U.S.A. 94: 8761–8766.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Alon T, Hemo I, Itin A, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1: 1024–1028.

    Article  CAS  PubMed  Google Scholar 

  44. Okada F, Rak J, St. Croix B, et al. (1998) Impact of oncogenes on tumor angiogenesis: mutant K-ras up-regulation of VEGF/VPF is necessary but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 35: 3609–3614.

    Article  Google Scholar 

  45. Grugel S, Finkenzeller G, Weindel K, et al. (1995) Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol Chem. 270: 25915–25919.

    Article  CAS  PubMed  Google Scholar 

  46. Saez E, Rutberg SE, Mueller E, et al. (1995) c-fos is required for malignant progression for skin tumors. Cell 82: 721–732.

    Article  CAS  PubMed  Google Scholar 

  47. Mazure NM, Chen EY, Yeh P, et al. (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56: 3436–3440.

    PubMed  CAS  Google Scholar 

  48. Larcher F, Robles AI, Duran H, et al. (1996) Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res. 56: 5391–5396.

    PubMed  CAS  Google Scholar 

  49. Volpert OV, Dameron KM, Bouck N. (1997) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14: 1495–1502.

    Article  CAS  PubMed  Google Scholar 

  50. Mazure NM, Chen EY, Laderoute KR, et al. (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-trans-formed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322–3331.

    PubMed  CAS  Google Scholar 

  51. Lingen MW, DiPietro LA, Solt DB, et al. (1997) The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation. Carcinogenesis 18: 329–338.

    Article  CAS  PubMed  Google Scholar 

  52. Arbiser JL, Moses MA, Fernandez CA, et al. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 94: 861–866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Enholm B, Paavonen K, Ristimaki A, et al. (1997) Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14: 2475–2483.

    Article  CAS  PubMed  Google Scholar 

  54. White FC, Benehacene A, Scheele JS, et al. (1997) VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation—evidence for divergent stabilization pathways. Growth Factors 14: 199–212.

    Article  CAS  PubMed  Google Scholar 

  55. Shirasawa S, Furuse M, Yokoyama N, et al. (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85–88.

    Article  CAS  PubMed  Google Scholar 

  56. Viloria-Petit AM, Rak J, Hung M-C, et al. (1997) Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol 151: 1523–1530.

    Google Scholar 

  57. Goldman CK, Kim J, Wong WL, et al. (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol. Biol Cell 4: 121–133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Goad DL, Rubin J, Wang H, et al. (1996) Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137: 2262–2268.

    Article  CAS  PubMed  Google Scholar 

  59. Kevil CG, De Benedetti A, Payne DK, et al. (1996) Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis. Int. J. Cancer 65: 785–790.

    Article  CAS  PubMed  Google Scholar 

  60. Zabrenetzky V, Harris CC, Steeg PS, et al. (1994) Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59: 191–195.

    Article  CAS  PubMed  Google Scholar 

  61. Sheibani N, Frazier WA. (1996) Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett. 107: 45–52.

    Article  CAS  PubMed  Google Scholar 

  62. Siemeister G, Weindel K, Mohrs K, et al. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56: 2299–2301.

    PubMed  CAS  Google Scholar 

  63. Mukhopadhyay D, Knebelmann B, Cohen HT, et al. (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Spl to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17: 5629–5639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Shweiki D, Itin A, Soffer D, et al. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initated angiogenesis. Nature 359: 843–845.

    Article  CAS  PubMed  Google Scholar 

  65. Shweiki D, Neeman M, Itin A, et al. (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 92: 768–772.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Ikeda E, Achen MG, Breier G, et al. (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 270: 19761–19766.

    Article  CAS  PubMed  Google Scholar 

  67. Stein I, Neeman M, Shweiki D, et al. (1995) Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and Deregulation with other ischemia-induced genes. Mol. Cell. Biol. 15: 5363–5368.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. D’Amore PA, Shima DT. (1996) Tumor angiogenesis: a physiological process or genetically determined? Cancer Metastasis Rev. 15: 205–212.

    Article  PubMed  Google Scholar 

  69. Thompson TC, Southgate J, Kitchener G, et al. (1989) Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917–930.

    Article  CAS  PubMed  Google Scholar 

  70. Fan Z, Mendelsohn J. (1998) Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol. 10: 67–73.

    Article  CAS  PubMed  Google Scholar 

  71. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gerhengorn MC, Mesri EA. (1998) G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86–89.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Lynda Woodcock and Cassandra Cheng for their excellent secretarial assistance. R. S. K.’s angiogenesis-related research is supported by grants from the Medical Research Council of Canada and the National Institutes of Health, U.S.A. (CA41223). R. S. K. is a Terry Fox Scientist of the National Cancer Institute of Canada.

Author information

Authors and Affiliations

  1. Biological Sciences Program, Division of Cancer Biology Research, Sunnybrook Health Science Centre, Research Building, S-218, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada

    Robert S. Kerbel, Alicia Viloria-Petit, Futoshi Okada & Janusz Rak

Authors
  1. Robert S. Kerbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia Viloria-Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Futoshi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Janusz Rak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Kerbel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerbel, R.S., Viloria-Petit, A., Okada, F. et al. Establishing a Link between Oncogenes and Tumor Angiogenesis. Mol Med 4, 286–295 (1998). https://doi.org/10.1007/BF03401737

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03401737

Keywords

Search

Navigation